Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Combination approach appears to improve chemotherapy response, boost anti-tumor immunity

Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.

3 Oct 2018

Researchers design new combination therapy for reducing NSCLC cell growth

Lung cancer is the leading cause of cancer death among men and women. About 85 percent of lung cancers are non-small cell lung cancer. For a handful of these patients, therapies that target specific genetic mutations are effective.

29 Sep 2018

Insilico Medicine collaborates with MAWI to develop multi-modal biomarkers of aging

Cardiovascular disease is the leading cause of death and disability in the world. On the eve of the annual World Heart Day, September 29th, Insilico Medicine, Inc., a Rockville-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announced a research collaboration agreement with MAWI, the next-generation consumer and clinical wearable company, the developer of one of the most accurate clinical-grade ECG wearable devices.

28 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

Crown Bioscience announces successful validation of well-characterized prostate cancer PDX models

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft models of prostate cancer.

27 Sep 2018

New cell-based profiling service from RBC and Promega

A new cell-based profiling service for drug discovery has been announced by RBC and Promega Corporation.

From Promega Corporation 27 Sep 2018

Cancer Research UK, Keystone Symposia collaborate for cancer-related research

Keystone Symposia and Cancer Research UK are pleased to announce their new collaboration consisting of a series of annual cancer-related scientific research conferences organized by Keystone Symposia in collaboration with Cancer Research UK.

26 Sep 2018

TGen-UNM consortium awarded NIH grant to discover new treatments for diabetic blindness

Diabetes is an increasing global epidemic that is expected to grow by more than 50 percent in the next two decades, leaving more than half a billion patients worldwide exposed to potentially life-altering medical complications, including pain and numbness in the feet, lost limbs, life-threatening disorders of the heart, liver and kidneys -- and even blindness.

26 Sep 2018

Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease

Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson's disease.

25 Sep 2018

Human-oriented perspective needed to better understand Parkinson's disease

Analysis published in Drug Discovery Today reveals the gap between animal models of Parkinson's disease and our understanding of the neurodegenerative processes underlying the disease, and calls for the implementation of modern, human biology-based technologies to better understand pathological processes and improve treatment outcome.

25 Sep 2018

New research suggests power of zebrafish as tool for cancer drug discovery

The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes.

24 Sep 2018

Logos Biosystems Introduces the New CELENA X High Content Imaging System

Logos Biosystems has released the all-new CELENA® X integrated High Content Imaging System, providing the complete solution for rapid high content image acquisition and quantitative analysis.

From Logos Biosystems 20 Sep 2018

Public launch of products and application solutions from Porvair Laboratory Division

Porvair has chosen Lab Innovations 2018 to bring together, for the first time on a single exhibition stand (G16), all the latest products and application solutions from its fast-growing Laboratory Division.

From Porvair Sciences Limited 20 Sep 2018

ALSAM Foundation invests additional $2 million for drug discovery and development projects

The ALSAM Foundation recently invested an additional $2 million to continue the Therapeutic Innovation Grants Program at the CU Skaggs School of Pharmacy and Pharmaceutical Sciences.

20 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Potential drugs to treat neurodegenerative diseases garner $3 million grant

A new four-year, $3 million grant will enable Scripps Research scientists to advance compounds that may protect neurons in diseases caused by toxic protein accumulation, including Parkinson's, ALS, Alzheimer's and Creutzfeldt-Jakob disease.

18 Sep 2018

Brigham Genomic Medicine program unravels 30 medical mysteries

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has plagued one or more family members.

18 Sep 2018

UNIST and Ulsan initiate research collaboration to develop human organs-on-chips

UNIST and Ulsan will initiate a research collaboration to develop human organs-on-chips in hoping to reduce the time and cost for new drug discovery.

18 Sep 2018

Thermo Fisher Scientific and Diamond collaborate to launch new cryo-EM capability for use in life sciences industry

An agreement to launch a new cryo-EM capability for use in the life sciences industry sector by Thermo Fisher Scientific, one of the world leaders in high-end scientific instrumentation, and Diamond Light Source, the UK’s national synchrotron and one of the most advanced scientific facilities in the world, was announced today at the official opening of the new national electron bio-imaging center at Diamond.

From Thermo Fisher Scientific – Electron Microscopy Solutions 14 Sep 2018

Drug Discovery News and Research

Further Reading

Combination approach appears to improve chemotherapy response, boost anti-tumor immunity

Researchers design new combination therapy for reducing NSCLC cell growth

Insilico Medicine collaborates with MAWI to develop multi-modal biomarkers of aging

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Crown Bioscience announces successful validation of well-characterized prostate cancer PDX models

New cell-based profiling service from RBC and Promega

Cancer Research UK, Keystone Symposia collaborate for cancer-related research

TGen-UNM consortium awarded NIH grant to discover new treatments for diabetic blindness

Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease

Human-oriented perspective needed to better understand Parkinson's disease

New research suggests power of zebrafish as tool for cancer drug discovery

Logos Biosystems Introduces the New CELENA X High Content Imaging System

Public launch of products and application solutions from Porvair Laboratory Division

ALSAM Foundation invests additional $2 million for drug discovery and development projects

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Potential drugs to treat neurodegenerative diseases garner $3 million grant

Brigham Genomic Medicine program unravels 30 medical mysteries

UNIST and Ulsan initiate research collaboration to develop human organs-on-chips

Thermo Fisher Scientific and Diamond collaborate to launch new cryo-EM capability for use in life sciences industry

eBook: Essential guide to organoids in drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News